choline has been researched along with Lymphoma, Large B-Cell, Diffuse in 10 studies
Lymphoma, Large B-Cell, Diffuse: Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition to prostate cancer recurrence, F-choline allowed partial initial staging of an incidental diffuse large B-cell lymphoma which was further confirmed and staged using F-FDG and a biopsy." | 7.88 | 18F-Choline and 18F-FDG PET/CT in a Patient With Diffuse Large B-Cell Lymphoma and Recurrent Prostate Cancer. ( De Leiris, N; Djaileb, L; Leenhardt, J; Riou, L; Vuillez, JP, 2018) |
| " Here, in diffuse large B-cell lymphoma (DLBCL), serum metabolomic analysis revealed that oncogenic MYC could induce aberrant choline metabolism by transcriptionally activating the key enzyme phosphate cytidylyltransferase 1 choline-α (PCYT1A)." | 7.85 | MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. ( Chen, SJ; Fei, XC; Gale, RP; Janin, A; Jiang, XF; Li, B; Wang, CF; Wang, L; Xiong, J; Zhao, WL; Zhao, Y; Zheng, Z, 2017) |
| " Here, we demonstrate through metabolomic profiling of patient plasma and cell lines that the KDACI panobinostat alters lipid metabolism and downstream survival signaling in diffuse large B-cell lymphomas (DLBCL)." | 3.88 | Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway. ( Assouline, SE; Cerchietti, L; Krumsiek, J; Mann, KK; Marullo, R; Patel, J; Pera, B; Phillip, JM; Román, L, 2018) |
| " In addition to prostate cancer recurrence, F-choline allowed partial initial staging of an incidental diffuse large B-cell lymphoma which was further confirmed and staged using F-FDG and a biopsy." | 3.88 | 18F-Choline and 18F-FDG PET/CT in a Patient With Diffuse Large B-Cell Lymphoma and Recurrent Prostate Cancer. ( De Leiris, N; Djaileb, L; Leenhardt, J; Riou, L; Vuillez, JP, 2018) |
| " Here, in diffuse large B-cell lymphoma (DLBCL), serum metabolomic analysis revealed that oncogenic MYC could induce aberrant choline metabolism by transcriptionally activating the key enzyme phosphate cytidylyltransferase 1 choline-α (PCYT1A)." | 3.85 | MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. ( Chen, SJ; Fei, XC; Gale, RP; Janin, A; Jiang, XF; Li, B; Wang, CF; Wang, L; Xiong, J; Zhao, WL; Zhao, Y; Zheng, Z, 2017) |
| " Using xenografts of the most common form of human NHL, diffuse large B-cell lymphoma (DLBCL), we have detected therapeutic response within one cycle of therapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), rituximab plus CHOP (RCHOP) or radiation (15 Gy) through detection of a decrease in lactic acid (Lac) or total choline (tCho) and an increase of apparent diffusion coefficients (ADC)." | 3.77 | NMR metabolic and physiological markers of therapeutic response. ( Delikatny, EJ; Glickson, JD; Goldstein, SC; Lee, SC; Loevner, LA; Mellon, EA; Nasta, SD; Nelson, DS; Pickup, S; Poptani, H; Reddy, R; Schuster, SJ; Svoboda, J; Wallace, SG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kowa, JY | 1 |
| Millard, T | 1 |
| Goldman, A | 1 |
| Sharma, RK | 1 |
| Attygalle, A | 1 |
| Mahalingam, P | 1 |
| Marshall, K | 1 |
| Welsh, L | 1 |
| Li, S | 1 |
| Mackinnon, A | 1 |
| Rich, P | 1 |
| Nicholson, E | 1 |
| Iyengar, S | 1 |
| El-Sharkawi, D | 1 |
| Chau, I | 1 |
| Cunningham, D | 1 |
| Sharma, B | 1 |
| Xiong, J | 2 |
| Wang, L | 1 |
| Fei, XC | 1 |
| Jiang, XF | 1 |
| Zheng, Z | 1 |
| Zhao, Y | 1 |
| Wang, CF | 1 |
| Li, B | 1 |
| Chen, SJ | 1 |
| Janin, A | 1 |
| Gale, RP | 1 |
| Zhao, WL | 2 |
| Pera, B | 1 |
| Krumsiek, J | 1 |
| Assouline, SE | 1 |
| Marullo, R | 1 |
| Patel, J | 1 |
| Phillip, JM | 1 |
| Román, L | 1 |
| Mann, KK | 1 |
| Cerchietti, L | 1 |
| De Leiris, N | 1 |
| Riou, L | 1 |
| Leenhardt, J | 1 |
| Vuillez, JP | 1 |
| Djaileb, L | 1 |
| Garzon, JG | 1 |
| Bassa, P | 1 |
| Moragas, M | 1 |
| Soler, M | 1 |
| Riera, E | 1 |
| Lee, SC | 2 |
| Poptani, H | 3 |
| Delikatny, EJ | 3 |
| Pickup, S | 3 |
| Nelson, DS | 3 |
| Schuster, SJ | 1 |
| Nasta, SD | 1 |
| Svoboda, J | 1 |
| Goldstein, SC | 1 |
| Wallace, SG | 1 |
| Loevner, LA | 1 |
| Mellon, EA | 1 |
| Reddy, R | 1 |
| Glickson, JD | 3 |
| Huang, MQ | 2 |
| Qiao, H | 1 |
| Wehrli, S | 1 |
| Adegbola, O | 1 |
| Potter, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Omic Technologies Applied to the Study of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers[NCT05834426] | 50 participants (Anticipated) | Observational | 2023-09-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for choline and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Immunoglobulin-producing tumors and myeloma proteins of mice.
Topics: Amino Acid Sequence; Amyloidosis; Animals; Antigens, Neoplasm; Antigens, Viral; Bence Jones Protein; | 1972 |
9 other studies available for choline and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Are treatment response assessment maps (TRAMs) and
Topics: Central Nervous System Neoplasms; Cerebellar Neoplasms; Choline; Fluorine Radioisotopes; Fluorodeoxy | 2021 |
MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.
Topics: Berberine; Cell Line, Tumor; Choline; Choline-Phosphate Cytidylyltransferase; Humans; Lymphoma, Larg | 2017 |
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.
Topics: Animals; Cell Line, Tumor; Cellular Reprogramming; Choline; Choline Kinase; Histone Deacetylase Inhi | 2018 |
Targetable Metabolic Vulnerability in Diffuse Large B-Cell Lymphoma.
Topics: Cellular Reprogramming; Choline; Humans; Lymphoma, Large B-Cell, Diffuse; Lysine; Metabolomics | 2018 |
18F-Choline and 18F-FDG PET/CT in a Patient With Diffuse Large B-Cell Lymphoma and Recurrent Prostate Cancer.
Topics: Aged, 80 and over; Choline; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Male; P | 2018 |
Incidental diagnosis of diffuse large B-cell lymphoma by 11C-choline PET/CT in a patient with biochemical recurrence of prostate cancer.
Topics: Aged; Carbon Radioisotopes; Choline; Humans; Incidental Findings; Lymphoma, Large B-Cell, Diffuse; M | 2014 |
NMR metabolic and physiological markers of therapeutic response.
Topics: Aged; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocol | 2011 |
In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2007 |
In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cell P | 2008 |